REG - GSK PLC - Admission to Trading

GSKAnnouncement

Today 15:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260323:nRSW7368Xa&default-theme=true

RNS Number : 7368X  GSK PLC  23 March 2026

Issued: 23 March 2026, London UK

 

Admission to trading

 

 

In conformity with PRM 1.6.4R, GSK plc notifies the market that ordinary
shares of 31¼ pence each ('Ordinary Shares') have been admitted to trading as
set out in the table below. The Ordinary Shares have been admitted to trading
under existing block listing admissions of Ordinary Shares in connection with
the "GlaxoSmithKline plc Share Save Plan 2012 and 2022".

 

 

 1a  Issuer name                                                                    GSK plc

 1b  Issuer LEI                                                                     5493000HZTVUYLO1D793

 2   Regulated market on which the securities have been admitted to trading         London Stock Exchange - Main Market

 3   Name, type and ISIN of the securities                                          Ordinary Shares of 31¼ pence each

                                                                                    ISIN: GB00BN7SWP63

 4   Number of further securities admitted to trading covered by this notification  96,525

 5   Total number of securities admitted to trading following admission             4,316,176,278

 6   Fungibility                                                                    Fully fungible with existing Ordinary Shares

 7   Date range covered by the notification                                         23 January 2026 - 20 March 2026

 8   Prospectus information                                                         N/A

 

 

V A Whyte

Company Secretary

 

23 March 2026

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at www.gsk.com
(http://www.gsk.com) .

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDZGZFZFKGVZM



            Copyright 2019 Regulatory News Service, all rights reserved